Table 4.
Pharmacodynamic parameters for bispectral index and subjective effects
| Parameter (unit) | Definition | Estimate | |||
|---|---|---|---|---|---|
| Bispectral index | Subjective effects | ||||
| Performance | Drowsiness | Drug effect | |||
| E0 (%) | Baseline response | 64.2 (14.0) | 7.1 (14.0) | 9.5 (24.6) | 20.7 (67.6) |
| Emax (mm or %) | Maximum response | 33.7 (62.9) | 86.8 (7.3) | 71.3 (11.4) | 78.5 (19.4) |
| EC50 (nmol/L) | NEs at 50 % of Emax | 3.9 (26.9) | 3.3 (21.1) | 4.4 (18.5) | 3.5 (15.6) |
| γ | Shape factor | 3.1 (87.0) | 4.0 (80.6) | 4.2 (57.0) | 4.1 (22.7) |
| ke0 (h−1) | Biophase rate constant | 15.6 (31.1) | 18.2 (77.5) | 18.3 (61.2) | 36.5 (46.6) |
| Inter-individual variability | |||||
| EC50 | 0.038 (51.2) [20] | 0.119 (41.0) [0.4] | 0.074 (51.9) [6] | 0.051 (81.3) [5] | |
| Residual variability | |||||
| Additive error (mm or %) | 7.99 (11.1) | 6.05 (45.1) | 11.70 (13.4) | 1.66 (13.6) | |
| Proportional error | - | 0.18 (36.7) | - | 0.38 (9.9) | |
(%) RSE, [%] shrinkage